U.S. Markets close in 36 mins

Cancer Companies to Watch

HENDERSON, NV / ACCESSWIRE / October 15, 2018 / Below we've highlighted a few companies working on treatments for different types of cancers that could potentially create value for shareholders.

One company with an impressive liver cancer treatment, Delcath Systems, Inc. (DCTH), has initiated a global phase 3 clinical trial in patients with intrahepatic cholangiocarcinoma (ICC), called ALIGN, using its product Melphalan/HDS.

That alone would be exciting enough but that's not all the company has going on. The company is enrolling their global registration trial called FOCUS for patients with Hepatic Dominant Ocular Melanoma (OM). which was recently amended from a randomized trial to a single-arm protocol, and now believes it can complete enrollment in mid-2019.

It is rare to find a biotech this far along without a huge following.

Some top stocks fighting cancer include: Delcath Systems, Inc. (DCTH), Dynavax Technologies Corp. (DVAX), Clovis Oncology (CLVS), ImmunoGen, Inc. (IMGN), and Tocagen, Inc. (TOCA).

Delcath Systems, Inc. (DCTH)

Market Cap: $6.77M Share Price: $1.21

Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, recently announced that results of a multicenter retrospective analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been published in the journal European Radiology. The study is the first analysis on the use of Delcath's PHP® Therapy for the treatment of ICC.

The retrospective analysis - Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicentre Study on Safety, Short Term Effects and Survival—was conducted by investigators in Germany, Italy, Netherlands, Spain and France with Dr. Steffen Marquardt of Hannover Medical School serving as lead author. The study evaluated 15 patients with ICC who were selected for PHP treatment after failing prior therapies. The patients were treated at nine hospitals throughout Europe between 2012 and 2016. Treatment outcomes were assessed by imaging every three months following PHP treatment.

Results of the study showed that after the first PHP treatment, one patient (7%) has a complete response (CR), two patients (13%) had a partial response (PR), and stable disease (SD) was observed in eight patients (53%). This equates to a disease control rate (CR+PR+SD) of 73%. Median overall survival (OS) was 26.9 months from initial diagnosis and 7.6 months from first PHP treatment. One-year OS from first PHP was 40%. Median progression free survival (PFS) was 122 days, and median hepatic progression free survival (hPFS) was 131 days. In this retrospective data collection, side-effects were potentially under-reported but were considered by the investigators to be tolerable and comparable to other systemic and local therapies. Investigators concluded that PHP Therapy provides “promising response rates in patients with ICC,” and that side-effects were tolerable and comparable to other treatment strategies.

Dynavax Technologies Corp. (DVAX)

Market Cap: $701.92M Share Price: $11.21

Dynavax Technologies Corporation announced that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada). Data will be presented in three individual sessions with data for advanced melanoma patients who are naïve to anti-PD-1 therapy being presented as a late-breaking abstract poster discussion, at the European Society for Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018 in Munich Germany.

Clovis Oncology, Inc. (CLVS)

Market Cap: $1.52B Share Price: $28.94

Clovis Oncology, Inc. CLVS announced that the FDA has granted Breakthrough Therapy designation for its cancer drug, Rubraca (rucaparib). The designation was granted for treating BRCA1/2 mutated metastatic castration resistant prostate cancer (mCRPC), based on initial data from phase II TRITON2 study. Currently, the study is evaluating the drug in mCRPC patients with BRCA mutations and ATM mutations.

ImmunoGen, Inc. (IMGN)

Market Cap: $1.12B Share Price: $7.53

ImmunoGen a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany. The poster will include initial safety and preliminary anti-tumor activity for 46 patients with platinum-resistant ovarian cancer (PROC), of whom 35 have medium or high folate receptor alpha (FRα) expression.

Tocagen, Inc. (TOCA)

Market Cap: $282.30M Share Price: $14.07

Tocagen, Inc. announced it has received Protocol Assistance from the European Medicines Agency (EMA) under the Company's PRIME (PRIority MEdicines) designation for Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine, extended-release) for the treatment of patients with recurrent high grade glioma (HGG). In particular, the EMA indicated that the statistical analyses, seamless design, and the use of overall survival as the primary endpoint in the ongoing Phase 3 Toca 5 clinical trial are appropriate for a potential marketing authorization application for Toca 511 & Toca FC.

Important Disclaimer, Please Read:

The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.

The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.

Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. DCTH

has paid, and continues to pay Regal to disseminate truthful and potentially material information regarding DCTH.

Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.

Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.

Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in DCTH can be found updated here: http://www.regalconsultingllc.com/disclaimer/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and ten thousand dollars total by Regal Consulting. LLC, for news commentary articles for DCTH. DCTH and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of DCTH in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC